№ 2 (199) 2026 р. С. 92–97

ПЛЕЙОТРОПНІ ЕФЕКТИ СТАТИНІВ У ГЕПАТОЛОГІЇ ТА ЗА НАЯВНОСТІ ВЕНОЗНИХ ТРОМБОЕМБОЛІЙ: АНАЛІЗ РЕАЛЬНОЇ ПРАКТИКИ (2016–2025)

М. М. Перепелюк

Одеський національний медичний університет, Одеса, Україна

DOI 10.32782/2226-2008-2026-2-13

Анотація. У статті представлено аналіз плейотропних ефектів статинів у гепатології та за наявності венозних тромбоемболій (ВТЕ), що базується на даних PubMed за період 2016–2025 рр. Розглянуто молекулярні механізми гепатопротекції. Наведено докази ефективності статинів у зниженні ризику декомпенсації цирозу печінки та профілактиці гепатоцелюлярної карциноми у пацієнтів із вірусними гепатитами. Окрему увагу приділено зниженню частоти первинних та рецидивуючих ВТЕ в умовах реальної практики.

Ключові слова: статини; плейотропні ефекти; цироз печінки; венозна тромбоемболія; реальна практика.

REFERENCES

  1. Abdulrazzak E, Fakhoury B, Jaan A, et al. Statin therapy and portal pressure reduction in cirrhosis: a systematic review and meta-analysis. Liver Int. 2025;45(10):e70326. https://doi.org/10.1111/liv.70326.
  2. Simon TG, Duberg AS, Aleman S, et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann Intern Med. 2019;171(5):318–327. https://doi.org/10.7326/M18-2753.
  3. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. 2017;4(2):e83–e93. https://doi.org/10.1016/S2352-3026(16)30184-3.
  4. Karim ME, Gustafson P, Petkau J, Tremlett H. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol. 2016;184(4):325–335. https://doi.org/10.1093/aje/kwv445.
  5. Suissa S, Dell’Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29(9):1101–1110. https://doi.org/10.1002/pds.5083.
  6. Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022;76(5):1100–1108. https://doi.org/10.1016/j.jhep.2021.12.034.
  7. Li R, Yuan M, Yu S, et al. Effect of statins on the risk of recurrent venous thromboembolism: a systematic review and meta-analysis. Pharmacol Res. 2021;165:105413. https://doi.org/10.1016/j.phrs.2020.105413.
  8. Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as a new indication for statins. Gut. 2020;69(5):953–962. https://doi.org/10.1136/gutjnl-2019-318237.
  9. Alvarado-Tapias E, Brujats A, Puente A, et al. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: a double-blind, placebo-controlled, randomized trial. Hepatology. 2025;82(1):140–154. https://doi.org/10.1097/HEP.0000000000001148.
  10. Gratacós-Ginès J, Pose E. Role of statins in cirrhosis and portal hypertension. Clin Liver Dis (Hoboken). 2023;22(2):50–57. https://doi.org/10.1097/CLD.0000000000000015.
  11. Rodríguez S, Raurell I, Torres-Arauz M, García-Lezana T, Genescà J, Martell M. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci Rep. 2017;7:40461. https://doi.org/10.1038/srep40461.
  12. Lastuvkova H, Alaei Faradonbeh F, Schreiberova J, et al. Atorvastatin modulates bile acid homeostasis in mice with diet-induced nonalcoholic steatohepatitis. Int J Mol Sci. 2021;22(12):6468. https://doi.org/10.3390/ijms22126468.
  13. Zhang X, Lou D, Fu R, Wu F, Zheng D, Ma X. Association between statins types with incidence of liver cancer: an updated meta-analysis. Curr Med Chem. 2024;31(6):762–775. https://doi.org/10.2174/0929867330666230701000400.
  14. Li X, Sheng L, Liu L, Hu Y, Chen Y, Lou L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol. 2020;20(1):98. https://doi.org/10.1186/ s12876-020-01222-1.
  15. Tarar ZI, Farooq U, Inayat F, et al. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. World J Exp Med. 2024;14(4):98543. https://doi.org/10.5493/ wjem.v14.i4.98543.
  16. Caro L, Prueksaritanont T, Fandozzi CM, et al. Evaluation of pharmacokinetic drug interactions of the direct-acting antiviral agents elbasvir and grazoprevir with pitavastatin, rosuvastatin, pravastatin, and atorvastatin in healthy adults. Clin Drug Investig. 2021;41(2):133–147. https://doi.org/10.1007/s40261-020-00974-8.
  17. Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters: an overview. Curr Drug Metab. 2021;22(5):328–341. https://doi.org/10.2 174/1389200222666210114122729.
  18. Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907. https://doi.org/10.1002/hep.29172.
  19. Sharma R, Simon TG, Hagström H, et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease. Clin Gastroenterol Hepatol. 2024;22(4):749–759.e19. https://doi.org/10.1016/ j.cgh.2023.04.017.
  20. Marrache MK, Rockey DC. Statins for treatment of chronic liver disease. Curr Opin Gastroenterol. 2021;37(3):200–207. https://doi.org/10.1097/MOG.0000000000000716.
  21. Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5(1):31–41. https://doi.org/10.1016/S2468-1253(19)30320-6.
  22. Amjad W, Jiang Z, Lai M. Statin use in cirrhosis and its association with incidence of portal vein thrombosis. J Gastroenterol Hepatol. 2024;39(5):955–963. https://doi.org/10.1111/jgh.16495.
  23. Ogura S, Yoshida Y, Kurahashi T, et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget. 2018;9:21022–21035. https://doi.org/10.18632/ oncotarget.24781.
  24. Wang Y, Wang W, Wang M, Shi J, Jia X, Dang S. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2022;2022:5389044. https://doi.org/10.1155/2022/5389044.
  25. Ruan J, Fang Y, Zhang X, Zhang Q, Song J. Statins exposure and adverse events in participants with chronic viral hepatitis: a meta-analysis based on cohort studies. npj Gut and Liver. 2025;2(1):7. https://doi.org/10.1038/s44355-025-00020-4.
  26. Cheung KS, Yeung YWM, Wong WS, Li B, Seto WK, Leung WK. Statins associate with lower risk of biliary tract cancers: a systematic review and meta-analysis. Cancer Med. 2023;12(1):557–568. https://doi.org/10.1002/cam4.4942.
  27. Mach F, Baigent C, Catapano AL, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–2539. https://doi.org/10.1093/eurheartj/ehy182.
  28. Kim HS, Lee SH, Kim H, et al. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea. J Clin Pharm Ther. 2016;41(3):266–272. https://doi.org/10.1111/jcpt.12377.
  29. Zhou XD, Kim SU, Yip TCF, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883–1892. https://doi.org/10.1136/gutjnl-2024-333074.
  30. Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol. 2021;21:120. https://doi.org/10.1186/ s12876-021-01704-w.
  31. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81. https://doi.org/10.1161/ ATV.0000000000000073.
  32. Rao AK, Del Carpio-Cano F, Janapati S, et al. Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (simvastatin in the prevention of COPD exacerbations) trial. J Thromb Haemost. 2021;19(7):1709–1717. https://doi.org/10.1111/jth.15282.
  33. Barale C, Frascaroli C, Senkeev R, Cavalot F, Russo I. Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia. Biomed Res Int. 2018;2018:6508709. https://doi.org/10.1155/2018/6508709.
  34. Skajaa N, Szépligeti SK, Horváth-Puhó E, Ghanima W, Hansen JB, Sørensen HT. Initiation of statins and risk of venous thromboembolism: population-based matched cohort study. Thromb Res. 2019;184:99–104. https://doi.org/10.1016/j.thromres.2019.11.003.
  35. Stewart LK, Sarmiento EJ, Kline JA. Statin use is associated with reduced risk of recurrence in patients with venous thromboembolism. Am J Med. 2020;133(8):930–935.e8. https://doi.org/10.1016/j.amjmed.2019.12.032.
Переглянути публікацію PDF